White Shield

Interest-Based Ads

Advertising Cookies: We would like to set third-party advertising cookies on your browser for this health-related website to help us serve relevant health-related advertisements to you about our products or services when you visit other websites. For more information, visit our Privacy Policy. Do you want to set these advertising cookies on this browser?

Patients HCP
This site is for US residents only.

Understanding the T315I Mutation
in Ph+ CML in Chronic Phase

Patient portrayal of a woman

A gene mutation may throw you off course

Some patients with Philadelphia chromosome–positive chronic myeloid leukemia (Ph+ CML) in chronic phase can develop what’s known as a gene mutation. A mutation is a change in the DNA of a cell.

Icon of gene mutation

Mutations may cause drug resistance

 

One of the goals of treatment for Ph+ CML in chronic phase is to see the number of leukemic cells in the blood go down. That may not happen for some people.

If the number of leukemic cells in your body starts going up instead of decreasing, your doctor may want to see if you have become resistant to your medication. This is often called “drug resistance.” It occurs when cancer cells are not responding to a medication.

 

There are 2 types of drug resistance:

 

  • Lack of response, also called primary drug resistance: The body does not respond to a medication

  • Secondary drug resistance: Over time, the body stops responding to a medication

 

Learn how SCEMBLIX may help

Testing for a mutation in the BCR‑ABL1 gene

In Ph+ CML in chronic phase, one of the causes of drug resistance is a mutation in the BCR‑ABL1 gene.
Here are some reasons why your doctor may decide to have you tested for a gene mutation:

  • You are not responding or are no longer responding to a medication

  • You are unable to reach a treatment milestone

To determine if you have a mutation, your doctor may order a BCR‑ABL1 kinase domain mutation analysis. This test looks for mutations in the BCR-ABL1 gene that may cause certain tyrosine kinase inhibitors (TKIs) that treat Ph+ CML in chronic phase to stop working.

 

Icon of magnifying glass

Identifying the T315I gene mutation

 

There are a number of different gene mutations that can occur in Ph+ CML in chronic phase, including a mutation called T315I. The only way to determine if you have a mutation is to undergo a BCR-ABL1 kinase domain mutation analysis. If this test shows that you have developed the T315I mutation, your doctor may consider whether to change your medication. 

SCEMBLIX is approved to treat Ph+ CML in chronic phase for those with the T315I mutation. 

 

Learn more about SCEMBLIX

 

Icon of question mark inside word balloon

Can you become resistant to your medication?

 

Over time, some people may stop responding to their medication for Ph+ CML in chronic phase. This may be caused by a gene mutation. If you aren’t seeing the results you had hoped for, ask your doctor if you should be tested for a gene mutation.